Last reviewed · How we verify

NCT05927233

Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery

Recruiting now Phase 4 Last updated 31 July 2024
What this trial tests

Phase 4 trial testing Methylprednisolone in Cyanotic Heart Disease in 60 participants. Currently enrolling.

Timeline
1 April 2023
Primary endpoint
30 April 2025
30 June 2025

Quick facts

Lead sponsorAga Khan University
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment60
Start date1 April 2023
Primary completion30 April 2025
Estimated completion30 June 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Aga Khan University

Who can join

Adults 1 Month to 18, any sex, with Cyanotic Heart Disease or Cardiopulmonary Bypass. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate the effects of steroids on the early postoperative inflammatory response in patients undergoing elective pediatric congenital cardiac surgery, requiring cardiopulmonary bypass (CPB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

Other recruiting trials for Cyanotic Heart Disease

Currently open trials in the same condition.

Other Aga Khan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05927233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing